Skip to content
Biodatica
Start free

Enfuego Therapeutics, Inc.

PITTSBORO, NC · also filed as None

OncologyRNAiFormed
Compare Sign in to watch

What changed

NIH R01 · $0.4M · Circle RNA Regulation of Lung Cancer Metastasis

3mo agoGrant renewalMar 23, 2026Source filing (opens the source filing in a new tab)

Momentum

60no change

Momentum 60 out of 100, unchanged since the last recompute.

Some recent activity, at a steady rate.

Runway (estimate)

~0months

The model puts this company near the end of its last raise.

Stage

Formed

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

21 pre-ticker oncology companies at Formed

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Filing

    Form D/A · $1.0M

    Oct 28, 2025

    Enfuego Therapeutics, Inc. · private raise, self-reported by the issuer

    SEC EDGAR · 0001866961-25-000002 (opens the source filing in a new tab)

  2. Grant

    R44 · $919k · non-dilutive

    Jul 5, 2023

    ENFUEGO THERAPEUTICS INC. · PI STANLAND, LYLA · NCI · award ends Jun 30, 2026 · Ligand-Directed KRAS G12V Mutant-Specific Therapeutics

    NIH RePORTER · NIH RePORTER 11135580 (opens the source filing in a new tab)

  3. Grant

    R01 · $399k · non-dilutive

    Apr 4, 2023

    UNIV OF NORTH CAROLINA CHAPEL HILL · PI PECOT, CHAD V · NCI · award ends Mar 31, 2028 · Circle RNA Regulation of Lung Cancer Metastasis

    NIH RePORTER · NIH RePORTER 11301898 (opens the source filing in a new tab)

  4. Grant

    P30 · $47k · non-dilutive

    Jun 1, 1997

    UNIV OF NORTH CAROLINA CHAPEL HILL · PI PECOT, CHAD V · NCI · award ends Nov 30, 2027 · Cancer Therapeutics Program

    NIH RePORTER · NIH RePORTER 11469225 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources